With a deep understanding of the pharmaceutical industry, Zeda has stood out in the main track of medical informatization. The company has built a core technology group of information and medicine cross-integration and innovation, built two information platforms of intelligent medicine production and intelligent medicine circulation, and extended its business to the agricultural field in the upstream of the industrial chain to promote the high-quality development of the medical and health industry through informationization.
Re-research and development, ecological performance has grown steadily.
In the semi-annual report, the company indicated that it would continue to increase its investment in R&D, make new technological breakthroughs, further strengthen its core technological advantages and raise market competition barriers.
During the reporting period, the company increased R&D expenses by 7,080,800 yuan, a year-on-year increase of 69.34%, and increased investment in equipment and software. By the end of the reporting period, the company had obtained 265,438+0 patents (including 65,438+08 invention patents) and 65,438+094 software copyrights. Among them, 202 1 added software copyright 13 in the first half of the year, and accumulated 39 software products.
The company always adheres to the concept of data-driven and fast service, and relies on cloud native ideas and machine learning technology to build a knowledge map describing the production state and appearance of enterprises, locate the scope of enterprise management indicators, and realize the transformation and upgrading of pharmaceutical manufacturing enterprises from digitalization to networking and intelligence.
From the product line, Zeda Yisheng tamped the product line of Zeda micro intelligent platform, realized agile development and continuous operation and maintenance based on the technical architecture of containerization+micro-service, further deepened the manufacturing execution system MES, manufacturing operation system MOM, quality management system QMS and resource management system EAM of industrial software system, and realized the closed loop of industrial interconnection data from acquisition access, process control, manufacturing execution, operation decision-making and reverse regulation.
According to the division of service sectors, in the service sector of pharmaceutical circulation enterprises, Zeda Lifelong has developed and promoted HIS system for various clinics, hospitals, small hospitals and other medical institutions, opened up the medical insurance data interface, realized one-stop clinic information solutions, and promoted the optimization of market resource allocation and circulation efficiency, aiming at creating a closed-loop service of "Internet medicine doctors". In this ecology, pharmaceutical companies, pharmaceutical companies, pharmacies, hospitals and patients can break the isolation and integrate with each other.
Continuous R&D investment and technological innovation have brought strong guarantee for Zeda Yisheng's business development, and the company's comprehensive strength, industry influence and brand building have been continuously improved. During the reporting period, the company successfully obtained the second-class ITSS certification and was rated as an AAA-level credit enterprise. The first domestic Guide to the Construction of Digital Village Standard System drafted by the company was officially released. Suzhou Zeda, a wholly-owned subsidiary, was also approved as the third batch of professional service providers of G60 Science and Technology Corridor Industrial Internet Platform in the Yangtze River Delta, and was selected as a member of China Intelligent Manufacturing System Solutions Alliance. As a joint unit, the "Thirteenth Five-Year Plan" intelligent manufacturing new model project of the Ministry of Industry and Information Technology also successfully passed the acceptance.
Seize the opportunity, expand the space and meet the golden period of development.
At present, under the joint action of policy guidance, technology drive and endogenous demand, the medical information industry is welcoming a golden period of development.
Zeda Yisheng is an enterprise that laid out the informationization of the whole pharmaceutical industry chain earlier in China. The company started from the pharmaceutical circulation information business, and after several years of efforts and independent innovation, it gradually expanded its business to the pharmaceutical production information, medical information, agriculture and other fields in the upstream of the industrial chain. In the field of medical information, the company has developed medical AI remote diagnosis and treatment, prescription, online consultation, auxiliary diagnosis and treatment and other service systems, as well as management platforms such as chronic disease management, electronic medical records and health records based on customer service. During the reporting period, the technical research and development capabilities of projects such as remote follow-up platform and smart medical big data analysis application platform were at the advanced level in China. At present, the company's business has covered more than 20 provinces, municipalities and autonomous regions such as Zhejiang Province, Fujian Province and Sichuan Province. The industrial software platform independently developed by Zeda Yisheng has realized localization substitution, breaking through the situation that international brands dominated the world in the past.
According to the statistics of the Operation Monitoring Coordination Bureau of the Ministry of Industry and Information Technology, from 20 10 to 2020, the revenue of China's software and information technology service industry will increase from 2010.36 trillion yuan to 8 16 trillion yuan in 2020, with a compound annual growth rate of19. In the first half of 2002/kloc-0, the business income of China's software and information technology service industry was 4.42 trillion yuan, a year-on-year increase of 23.2%.
According to industry insiders, compared with the high concentration of foreign pharmaceutical industry, the concentration of domestic pharmaceutical enterprises is also increasing rapidly, and the information market of large pharmaceutical enterprises will be further opened. In addition, because the pharmaceutical industry is closely related to people's health, the medium-and long-term strategic planning in the health field at the national level will guide the big health field into a new stage of digital management.
In the agricultural field, Zeda devoted himself to "planting one thing" during the reporting period, training long-term planting algorithms, and improving the quality and efficiency of agricultural products production through scientific breeding and intelligent planting; At the same time, improve the agricultural information platform, focus on agricultural industrial parks and regional agricultural products, iteratively upgrade the Internet of Things and traceability platform, build a brand management and control system with one standard and two yards, and enhance the brand credibility of agricultural products; In rural areas, it is necessary to build a rural database and realize the collection, integration, analysis and * * * sharing of agricultural data resources through data collection, data cleaning and governance, data operation and monitoring.
In the process of development, Zeda expanded its business coverage on the one hand, and deepened its services to the pharmaceutical circulation ecosystem integrating planting enterprises, pharmaceutical enterprises, pharmaceutical companies, pharmacies, hospitals and patients on the other hand, and finally realized the optimization of the pharmaceutical health industrial chain. The company deeply focuses on the field of medicine and health, constructs the core industry map, and in the process of deep integration of industrialization and informatization, takes the improvement of industry process level as a breakthrough to expand the information business in all medical fields such as biopharmaceuticals and chemical pharmaceuticals.